CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid‑in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balances (in shares) at Dec. 31, 2020	85,299,885
Beginning Balances at Dec. 31, 2020	$ 81,658,000
Redeemable Convertible Preferred Stock
Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)		53,522,099
Issuance of redeemable convertible preferred stock, net of issuance costs		$ 115,831,000
Ending Balances (in shares) at Mar. 31, 2021	138,821,984
Ending Balances at Mar. 31, 2021	$ 197,489,000
Beginning Balances (in shares) at Dec. 31, 2020			1,244,139
Beginning Balances at Dec. 31, 2020	(41,490,000)		$ 0	$ 1,021,000	$ 0	$ (42,511,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			16,453
Issuance of common stock upon exercise of stock options	29,000			29,000		0
Vesting of restricted common stock (in shares)			4,326
Vesting of early exercised options (in shares)			6,529
Vesting of early exercised options	8,000			8,000
Stock‑based compensation	164,000			164,000
Other comprehensive loss	0
Net loss	(8,380,000)					(8,380,000)
Ending Balances (in shares) at Mar. 31, 2021			1,271,447
Ending Balances at Mar. 31, 2021	$ (49,669,000)		$ 0	1,222,000	0	(50,891,000)
Beginning Balances (in shares) at Dec. 31, 2020	85,299,885
Beginning Balances at Dec. 31, 2020	$ 81,658,000
Ending Balances (in shares) at Dec. 31, 2021	0
Ending Balances at Dec. 31, 2021	$ 0
Beginning Balances (in shares) at Dec. 31, 2020			1,244,139
Beginning Balances at Dec. 31, 2020	$ (41,490,000)		$ 0	1,021,000	0	(42,511,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised options (in shares)	111,756
Ending Balances (in shares) at Dec. 31, 2021			31,224,336
Ending Balances at Dec. 31, 2021	$ 298,718,000		$ 3,000	392,384,000	0	(93,669,000)
Ending Balances (in shares) at Mar. 31, 2022	0
Ending Balances at Mar. 31, 2022	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	24,891		24,891
Issuance of common stock upon exercise of stock options	$ 50,000			50,000
Vesting of early exercised options (in shares)	96,532		15,224
Vesting of early exercised options	$ 35,000			35,000
Stock‑based compensation	1,794,000			1,794,000
Other comprehensive loss	(1,535,000)				(1,535,000)
Net loss	(21,671,000)					(21,671,000)
Ending Balances (in shares) at Mar. 31, 2022			31,264,451
Ending Balances at Mar. 31, 2022	$ 277,391,000		$ 3,000	$ 394,263,000	$ (1,535,000)	$ (115,340,000)